copanlisib + itraconazole

This item represents the **co-administration of copanlisib and itraconazole**, not a fixed-dose combination product. **Copanlisib** is a small molecule, intravenous, pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, with predominant activity against PI3K-alpha and delta isoforms. It is primarily indicated for relapsed follicular lymphoma and other indolent non-Hodgkin lymphomas. **Itraconazole** is a triazole antifungal agent that is a strong inhibitor of CYP3A4. When these drugs are co-administered, itraconazole can significantly affect copanlisib pharmacokinetics by inhibiting its metabolism, potentially increasing copanlisib exposure. This combination is not an approved therapy and is of interest primarily in the context of a drug-drug interaction or for clinical pharmacology considerations, such as the need for copanlisib dose adjustment when co-administered with strong CYP3A4 inhibitors like itraconazole[1][3].